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 Hypertension  has  long  been  called  as  the  silent  killer  as  because  when  its 
symptoms are apparent the damage is already done to  the system and to add to the 
worse they are mostly irreversible.
The  phenomenon  of   hypertension was first  characterized at  the turn of  the 
previous  century,  when  Riva-Rocci[6] developed  the  prototype  of  the  modern 
sphygmomanometer and so allowed the routine measurement of BP. Korotkov [7] then 
perfected the sphygmomanometric technique by describing the sounds heard over the 
brachial  artery as the pressure in the cuff is  reduced.  In general,  the upper limits of 
normal BP in older persons had been considered to be a systolic value of 140 mm Hg 
and a diastolic value of 90 mm Hg. These figures have been adjusted downward to the 
point  that  readings  in  excess  of  120/80  mm  Hg  may  be  considered  abnormal. [8] 
Population studies suggest that BP is a continuous variable, with no absolute dividing 
line between normal and abnormal values.[14]A recent report on the   global burden of 
hypertension indicates that nearly  1 billion adults (more than a quarter of the world’s 
population) had hypertension in 2000, and this is predicted to increase to 1.56 billion by 
2025(2). Subjects  with  hypertension  are  known to  have  a  two-fold  higher    risk  of 
developing coronary artery disease (CAD), four times higher risk of congestive heart 
failure and seven times higher risk of cerebrovascular disease and stroke  compared to 
normotensive subjects(3) 
Hypertension has   been identified as one of the leading risk factors for   mortality, 
and is ranked third as a cause of disability adjusted  life- ears. (4)  Existing data suggests 
that  the  prevalence  of  hypertension  has  remained  stable  or  has   decreased  in 
economically developed countries during   the past decade, while it has increased in 
developing  countries.(5)  However, the increase in the prevalence rates of hypertension 
needs  to  be  quantified  so  as  to  plan   for  effective  prevention  strategies  which  are 
urgently  needed in developing countries.
However,  in  spite  of  its  proven  association  with  all  clinical  associations  of 
atherosclerosis including peripheral vascular diseases hypertension is one disease which 
is more commonly mismanaged. The awareness about the disease and its complications 
are poor as  only less  than 30% of  even known hypertensives have a good optimal 
control even in western population.
Less studies are there in newly diagnosed hypertensives and the prevalence of 
complications and risk  factors  among them.  Being the diabetes  capital  of  the world 
already India is also projected to become the Hypertensive capital of the world by 2025. 
In this context this study is aimed in the evaluation of newly detected hypertensives in a  
tertiary care centre  at Chennai  and  the prevalence of associated risk factors for future 
cardio vascular incident among them.  
AIMS AND OBJECTIVES OF THE STUDY
• To study the complete profile of newly diagnosed hypertensives.
• To stage them
• To study the prevalence of end organ damage among them.
• To study the prevalence of metabolic syndrome, erectile dysfunction and coronary 
heart disease equivalents among them.
• To calculate Framingham risk score for all of them
                  
REVIEW OF LITERATURE
PREVALENCE:
Hypertension is common among the population. In a Population study conducted 
in  suburban  Chennai   the  prevalence  of   hypertension  was  20%  (1).  However  its 
prevalence varies with population and geographical area studied.
Similarly the rate of complications and associated risk factors  also vary with 
population studied. In the CURES study Mohan et al observed that in the HT population 
the  rate  of  cardio   vascular   risk  factors   was  twice  that  of  non  hypertensives  on 
diagnosis.
PHYSIOLOGY OF BLOOD PRESSURE
Before proceeding with a discussion of the pathophysiology of hypertension, it is 
necessary to briefly review the factors that control BP homeostasis. 
BP is defined as  BP= CO*TVR
                                          = SV*HR*TVR
where BP = blood pressure, CO = cardiac output, HR = heart rate, SV = stroke 
volume, and TPR = total peripheral resistance.
Body  volume  varies  directly  with  total  body  Na  content  because  Na  is  the 
predominant extracellular solute that retains water within the extracellular space. One 
primary function of the kidneys is to regulate Na and water excretion, and consequently, 
they also provide a dominant role in the long-term control of BP.. This phenomenon has 
been  referred  to  as  pressure  natriuresis. [9]  [10].  The  second  mechanism employs  the 
RAAS, which directly controls peripheral vascular resistance and renal reabsorption of 
Na and water. Accordingly, the renin system normally functions as a long-term regulator 
of BP homeostasis. [12] [11]
Pressure Natriuresis 
Pressure  natriuresis  is  the  increase  in  urinary  excretion  of  Na  and  water  that 
occurs when arterial pressure increases. As a consequence of this compensatory renal 
response,  BP  is  maintained  within  the  normal  range.[14] Accordingly,  the  kidney 
functions  as  a  servocontroller  of  arterial  pressure  and  exhibits  an  infinite  negative 
feedback  gain  for  the  long-term  regulation  of  arterial  pressure  by  adjusting  blood 
volume.[13]
Renin-Angiotensin-Aldosterone System 
The ability to maintain normal BP at Na intakes ranging from levels well below to 
those far above normal is a direct effect of the circulating levels of renin-Ang II. The 
kidneys secrete the enzyme renin from the juxtaglomerular cells in response to a variety 
of  normal  or  abnormal  phenomena  that  reduce  arterial  BP,  renal  perfusion,  or  Na 
chloride load to the macula densa (MD).[12] These include changes in posture or effective 
circulating  fluid  volume  (i.e.,  Na  depletion,  hemorrhage,  HF,  nephrotic  syndrome, 
cirrhosis). Baroreceptors in the afferent arterioles, chloride-sensitive receptors in the MD 
and  juxtaglomerular  apparatus,  and  efferent  renal  sympathetic  nerve  activity  all 
participate in this feedback control. [15] [16] In this way, circulating renin levels are tightly 
regulated and subject to constant physiologic adjustment. [17] 18] 
The  kidney  secretes  renin  into  the  peripheral  circulation  and,  thus,  it  has 
characteristics  of  both  an  enzyme  and  a  hormone.[19] The  half-life  of  renin  in  the 
circulation is about 15-20 minutes, with its metabolism occurring primarily in the liver. 
Under normal circumstances, changes in the biosynthesis and renal secretion of renin are 
the primary determinants of plasma Ang II formation. Thus, renin secretion is the rate-
limiting  step  in  the  regulation  of  the  renin-angiotensin  system[19).  Renin  cleaves  the 
inactive Ang I, from angiotensinogen Ang I is then converted to the octapeptide, Ang II 
by ACE, located in the circulation.
Ang II  is  the first  effector  hormone of  the system.  It  increases BP in several 
different ways, each of which is mediated by the AT1. First, it exerts powerful, direct, 
and immediate vasoconstriction and, thus, increases peripheral vascular resistance [20] [21] 
[22] Second,  it  rapidly  stimulates  Na  reabsorption  via  proximal  nephron  and  at  the 
medullary thick ascending limb   [23]  [24]. Third, and at a slower pace, Ang II stimulates 
aldosterone biosynthesis and secretion by the adrenal zona glomerulosa. 
Aldosterone stimulates electrogenic reabsorption of Na by principal cells in the 
collecting duct and by mineralocorticoid responsive tissue in the colon and sebaceous 
and salivary glands. Retained Na is responsible for increased extracellular fluid volume 
that increases BP hydraulically and also heightens vascular sensitivity to Ang II and 
other vasoconstrictors. [25] Together, these multiple effects combine to raise BP and to 
restore fluid volume to the point at which the initial signals for renin release (i.e., low 
BP and renal perfusion pressure) are attenuated or abolished.
In the normotensive individual, when salt intake is increased, circulating renin-
Ang II levels decrease and BP remains within the normal range. Conversely, when Na 
intake decreases, renin-Ang II levels increase without a significant deviation in BP. [26] 
Thus, BP is kept relatively constant, even when Na intake is varied from 10 to 1500 
mEq/day, because of the reciprocal change in Ang II levels and body Na content[27] .
Cytochrome P-450–Dependent Metabolites of Arachidonic Acid 
Arachidonic acid is metabolized primarily by CYP enzymes in the brain, lung, 
kidney, and peripheral vasculature to 20-hydroxyeicosatetraenoic acid (20-HETE) and 
epoxyeicosatrienoic  acids (EETs).[28] EETs,  which are  derived from endothelial  cells, 
promote vasodilatation by activating K+ channels and hyperpolarizing vascular smooth 
muscle  cells.  By contrast,  20-HETE vasoconstricts  vascular  smooth  muscle  cells  by 
reducing the open-state probability of Ca2+-activated K+ channels. Both EETs and 20-
HETEs play an important role in renal vascular tone and Na excretion, and thus, it has 
been proposed that they participate in the pressure natriuresis relationship
Nitric Oxide 
Renal  medullary  blood  flow  plays  a  central  role  in  the  maintenance  of  BP 
homeostasis. NO regulates medullary renal vascular resistance, natriuresis, and diuresis 
and,  therefore,  contributes  importantly  to  the  pressure  natriuresis  relationship.  [29]  [30] 
There  is  considerable  evidence  that  NO  serves  an  important  counterregulatory  role 
within the renal medullary circulation. 
SYSTEMIC  REGULATION  BY  THE  NERVOUS  SYSTEM 
Neural 
Although  the  arterioles  and  the  other  resistance  vessels  are  most  densely 
innervated, all blood vessels except capillaries and venules contain smooth muscle and 
receive  motor  nerve  fibers  from the  sympathetic  division  of  the  autonomic  nervous 
system.  The  fibers  to  the  resistance  vessels  regulate  tissue  blood  flow  and  arterial 
pressure.. 
Vessel innervation 
Noradrenergic fibers end on vessels in all parts of the body(31). The noradrenergic 
fibers are vasoconstrictor in function. In addition to their vasoconstrictor innervation, the 
resistance vessels of the skeletal muscles are innervated by vasodilator fibers, which, 
although  they  travel  with  the  sympathetic  nerves,  are  cholinergic  (the  sympathetic 
vasodilator  system.)  
There is no tonic discharge in the vasodilator fibers, but the vasoconstrictor fibers to 
most  vascular  beds  have  some  tonic  activity.  
Cardiac innervation 
Impulses in the noradrenergic sympathetic nerves to the heart increase the cardiac 
rate (chronotropic effect) and the force of cardiac contraction (inotropic effect). They 
also  inhibit  the  effects  of  vagal  stimulation,  probably  by release  of  neuropeptide  Y, 
which is a cotransmitter in the sympathetic endings. Impulses in the cholinergic vagal 
cardiac fibers decrease the heart rate. There is a moderate amount of tonic discharge in 
the cardiac sympathetic nerves at rest, but there is a good deal of tonic vagal discharge 
(vagal tone).
VasomotorControl 
Spinal  reflex  activity  affects  blood  pressure,  but  the  main  control  of  blood 
pressure is exerted by groups of neurons in the medulla oblongata that are sometimes 
called collectively the vasomotor area or vasomotor centre. 
When  vasoconstrictor  discharge  is  increased,  there  is  increased  arteriolar 
constriction and a rise in blood pressure. Heart rate and stroke volume are increased 
because  of  activity  in  the  sympathetic  nerves  to  the  heart,  and  cardiac  output  is 
increased. There is usually an associated decrease in the tonic activity of vagal fibres to 
the heart. Conversely, a decrease in vasomotor discharge causes vasodilation , a fall in 
blood pressure, and an increase in the storage of blood in the venous reservoirs. There is 
usually a concomitant decrease in heart rate, but this is mostly due to stimulation of the 
vagal innervations of the heart
Baroreceptors 
The baroreceptors are stretch receptors in the walls of the heart and blood vessels. 
The  carotid  sinus and  aortic  arch receptors  monitor  the  arterial  circulation.  The 
baroreceptors are stimulated by distention of the structures in which they are located, 
and so they discharge at an increased rate when the pressure in these structures rises. 
increased  baroreceptor  discharge  inhibits the  tonic  discharge  of  the  vasoconstrictor 
nerves  and  excites the  vagal  innervation  of  the  heart,  producing  vasodilation, 
venodilation, a drop in blood pressure, bradycardia, and a decrease in cardiac output. 
Carotid Sinus & Aortic Arch 
The carotid sinus is a small dilation of the internal carotid artery just above the 
bifurcation  of  the  common  carotid  into  external  and  internal  carotid  branches  . 
Baroreceptors are located in this dilation. They are also found in the wall of the arch of 
the aorta.. The carotid sinus nerves and vagal fibers from the aortic arch are commonly 
called the buffer nerves. 
Buffer Nerve Activity 
At normal blood pressure levels, the fibers of the buffer nerves discharge at a low 
rate . When the pressure in the sinus and aortic arch rises, the discharge rate increases; 
and when the pressure falls, the rate declines. 
The carotid receptors respond both to sustained pressure and to pulse pressure(32). 
A decline in carotid pulse pressure without any change in mean pressure decreases the 
rate of baroreceptor discharge and provokes a rise in blood pressure and tachycardia. 
The receptors also respond to changes in pressure as well as steady pressure; when the 
pressure is fluctuating, they sometimes discharge during the rises and are silent during 
the falls at  mean pressures at which if  there were no fluctuations,  there would be a 
steady discharge. 
From the foregoing discussion, it is apparent that the baroreceptors on the arterial 
side of the circulation, their afferent connections to the vasomotor and cardioinhibitory 
areas,  and  the  efferent  pathways  from  these  areas  constitute  a  reflex  feedback 
mechanism that  operates to  stabilize  the blood pressure and heart  rate.  Any drop in 
systemic arterial pressure decreases the inhibitory discharge in the buffer nerves, and 
there is a compensatory rise in blood pressure and cardiac output. Any rise in pressure 
produces dilation of the arterioles and decreases cardiac output until the blood pressure 
returns to its previous normal level.
PATHOPHYSIOLOGY OF HYPERTENSION
Several lines of evidence further support the conclusion that the kidney plays an 
essential  role  in  the pathogenesis  of  hypertension.  First,  in  human hypertension and 
virtually all experimental models of hypertension, the ability to excrete Na is impaired at 
normal BP. [9]  [10]  [33] This phenomenon has been demonstrated in renal artery stenosis, 
aortic  coarctation,  mineralocorticoid  hypertension,  surgical  reduction  of  renal  mass, 
glomerulonephritis, long-term infusion of vasoconstrictors,[34] and all genetic rat models 
of hypertension. Second, when renal excretory function is dampened by infusion of Na- 
and water-retaining hormones (e.g.,  vasopressin,  Ang II,  aldosterone),  an increase in 
renal perfusion pressure is required to restore Na and volume homeostasis. Third, all 
effective antihypertensive drugs shift the pressure natriuresis relationship back to control 
levels.[34] Fourth,  the  BP level  in  a  human  or  experimental  animal  renal  transplant 
recipient is directly related to the BP of the kidney donor. For example, to maintain a 
similar BP level in renal transplant recipients without familial hypertension, a kidney 
received from a hypertensive donor determines a 10-fold larger increase in the required 
dose  of  antihypertensive  therapy  than  the  transplantation  of  a  kidney  from  a 
normotensive donor.[35]
Vascular Remodeling and Pathologic Changes 
In  primary hypertension,  the column of blood in the arterial  tree  between the 
aortic  valves  and  the  capillaries  moves  at  abnormally  high  pressure  throughout  the 
cardiac cycle of contraction and relaxation. However, cardiac output is usually normal or 
close to normal. Thus, the main determinant of the sustained elevated BP is an increase 
in peripheral resistance. The increase in vascular resistance, a cardinal characteristic of 
diastolic hypertension, is commonly related to excessive vasoconstriction of arteriolar 
smooth muscle, although it can also result, at least in part, from structural changes in 
these  arterioles,  from  increased  blood  viscosity,  or  even  perhaps  from  increased 
extravascular (interstitial) pressure.[36]
Renal vein catheterization data also indicate that the earliest physiologic lesion of 
essential hypertension is vascular. Under normal circumstances, peripheral resistance is 
determined  predominantly  by  the  precapillary  vessels  with  a  lumen  diameter  of 
approximately 100 to 300 mm. [37] [38] In human hypertension and in experimental animal 
models of  hypertension,  structural  changes in these resistance vessels are commonly 
observed. In primary hypertension, the outer diameter and lumen of these vessels are 
smaller, the media-to-lumen ratio is greater, but the cross-sectional area of the media is 
not different from that of age- and sex-matched normotensive subjects. This pathologic 
alteration is termed eutrophic remodeling.[39]
The  LaPlace  relationship  illustrates  that  these  characteristic  vascular  changes 
provide an adaptive function by reducing wall tension as follows:T= P* (r/w)
where T = tension per unit wall layer, P = transmural pressure, r = radius, and w = 
wall thickness.
It is apparent from this relationship that, when the P increases, T remains constant 
only  if  the  ratio  of  radius  to  wall  thickness  (r/w)  decreases  proportionately  by  w 
thickening and/or r decreasing. When this alteration of vascular structure occurs within 
the resistance axis,  located from the aortic valve up to and including the glomerular 
capillary membrane, then it contributes to the long-term elevation in BP.[14]
In  human  essential  hypertension,  increasing  evidence  supports  the  view  that 
vascular  remodeling,  rather  than  growth,  is  the  predominant  change  occurring  in 
resistance vessels. The increase in media-to-lumen ratio of the resistance vessels occurs 
by the addition of material to either the outer or the inner surfaces of the blood vessel 
wall.[40] For this to occur, a reduction in the external diameter of the blood vessel is 
required. Restructuring of the vessel wall is the consequence of several events, which 
appear  to  include  increased  vasoconstriction,  increased  matrix  deposition,  increased 
apoptosis in the periphery of the vessel with enhanced growth toward the lumen, and 
changes in motility of smooth muscle cells. [41] [42] [43]
Ang  II  stimulates  vascular  smooth  muscle  cell  hypertrophy  and  hyperplasia, 
extracellular  matrix  production,  and  collagen  degradation,  which  contribute  to  the 
remodelling of resistance vessels.[39] Ang II, via NAD(P)H oxidase, also has significant 
pro inflammatory actions in the vascular wall,  stimulating the production of reactive 
oxygen species, such as superoxide (O22-) and H2O2, cytokines, adhesion molecules, and 
activation of redox-sensitive inflammatory genes.  [44] [45] Vascular O22- and H2O2 influence 
redox-sensitive  signaling  molecules  that  regulate  the  vascular  smooth  muscle  cell 
responses involved in remodeling.[39]
The  signficance  of  Ang  II  in  the  pathogenesis  of  vascular  remodeling  was 
reinforced in studies of human hypertension in which treatment with an ACE inhibitor or 
ARB, but not a β-blocker, corrected the structure and improved the function of small 
arteries.[39] This response appeared to be independent of the BP, which was equivalent in 
each  treatment  group.  Activation  of  peroxisome  proliferator-activated  receptors 
(PPARs), which participate in the regulation of cell growth and migration, oxidant stress, 
and inflammation in the cardiovascular system[46] may also attenuate Ang II-mediated 
vascular remodeling. [47] (48)
Impaired Pressure Natriuresis 
Disruption  of  the  pressure  natriuresis  relationship  is  a  fundamental  aspect  of 
human hypertension and all experimental models of hypertension.
Sympathetic Nervous System
Several  studies suggest  that  patients  with primary hypertension have impaired 
circulatory  homeostasis  with  abnormal  vascular  reactivity.  When  monitored  for  24 
hours, these patients generally show a resetting of their diurnal BP profile to a higher 
level, with somewhat wider than normal fluctuations in BP.[49] They may also have a 
wider BP response to various psychic or physical stimuli. They may exhibit abnormal 
responses  (fainting)  to  venous  occlusion  of  the  legs  and  can  exhibit  such  other 
vasomotor phenomena as increased flushing, tachycardia, and sweating in response to 
various stimuli.[50] These phenomena are not necessarily or consistently related to the 
hypertension itself. They may reflect a relative instability of the individual's circulation 
compared with that of normo tensive people, whose BP level is closer to the midpoint of 
defensive buffering systems that protect against assaults on the circulation.
COMPLICATIONS OF HT
Cardiovascular Disease 
Life  insurance  statistics  have  established  that  hypertensive  individuals,  as  a 
population, have shortened survival and that this vulnerability correlates broadly with 
increasing levels of arterial BP.[53] The Framingham Heart Study [51] [52] confirmed these 
findings and demonstrated that high BP is a leading risk factor predisposing to stroke, 
HF, heart attack, and kidney failure. Whether and how soon these complications occur in 
a specific hypertensive patient appears to be strongly determined by the concurrence of 
other risk factors, such as LVH, diabetes, smoking and hypercholesterolemia.
Heart Failure
Hypertension  is  the  most  common  condition  antedating  HF,  with  a  two-  to 
threefold higher risk than for normotensive subjects and with a graded increase in risk at 
higher pressure. [55] [56] In the Framingham population,[54] more than 90% of patients with 
symptomatic HF had a history of hypertension. Systolic, diastolic, and pulse pressures 
were  related  to  the  risk  of  HF  in  the  Framingham  cohort,[55] but  the  relation  was 
strongest for systolic and pulse pressures. This risk is amplified further when ECG-LVH 
or echo-LVH are present 
Kidney
Primary renal disease is the most common etiology of secondary hypertension. 
Conversely, hypertension is a risk factor for renal injury and ESRD. The increased risk 
associated with high blood pressure is graded, continuous, and present throughout the 
entire  distribution  of  blood  pressure  above  optimal.  Renal  risk  appears  to  be  more 
closely related to systolic than to diastolic blood pressure, and black men are at greater 
risk than white men for developing ESRD at every level of blood pressure. 
Microalbuminuria 
Microalbuminuria, defined  as  urinary  albumin  excretion  between  30  and  299 
mg/mg creatinine, is the earliest sign of nephropathy.[57] It occurs in approximately 6% to 
40% of individuals with primary hypertension, with the prevalence increasing with age 
and  duration  of  hypertension. [58]  [59)Microalbuminuria  is  a  well-defined  marker  for 
increased risk  of  CVD in  patients  with  diabetes  .  In   a  study  of  more  than 11,000 
nondiabetic  individuals  with  hypertension,  the  presence  of  microalbuminuria  was 
associated with a significantly higher prevalence of LVH, coronary artery disease, MI, 
hyperlipidemia,  and  peripheral  vascular  disease.[60] These  findings  relating  albumin 
excretion with adverse outcomes in nondiabetic subjects have been reported in other 
large-population studies. [59] 
Brain
Hypertension  is  an  important  risk  factor  for  brain  infarction  and  hemorrhage. 
Approximately  85% of  strokes  are  due  to  infarction  and  the  remainder  are  due  to 
hemorrhage,  either  intracerebral  hemorrhage  or  subarachnoid  hemorrhage.  The 
incidence of stroke rises progressively with increasing blood pressure levels, particularly 
systolic blood pressure in individuals >65 years. Treatment of hypertension convincingly 
decreases the incidence of both ischemic and hemorrhagic strokes. 
Hypertension is also associated with impaired cognition in an aging population, 
and longitudinal studies support an association between mid-life hypertension and late-
life cognitive decline. Hypertension-related cognitive impairment and dementia may be 
a  consequence  of  a  single  infarct  due  to  occlusion  of  a  "strategic"  larger  vessel  or 
multiple lacunar infarcts due to occlusive small vessel disease resulting in subcortical 
white matter ischemia. Several clinical trials suggest that antihypertensive therapy has a 
beneficial  effect  on  cognitive  function,  although  this  remains  an  active  area  of 
investigation. 
PERIPHERAL ARTERIES
In addition to contributing to the pathogenesis of hypertension, blood vessels may 
be a target organ for atherosclerotic disease secondary to long-standing elevated blood 
pressure.  Hypertensive  patients  with  arterial  disease  of  the  lower  extremities  are  at 
increased risk for future cardiovascular disease. Although patients with stenotic lesions 
of the lower extremities may be asymptomatic, intermittent claudication is the classic 
symptom of PAD. This is characterized by aching pain in the calves or buttocks while 
walking  that  is  relieved  by  rest.  The  ankle-brachial  index  is  a  useful  approach  for 
evaluating PAD and is defined as the ratio of noninvasively assessed ankle to brachial 
(arm) systolic blood pressure. An ankle-brachial index < 0.90 is considered diagnostic of 
PAD and is  associated with >50% stenosis  in at  least  one major  lower  limb vessel. 
Several studies suggest that an ankle-brachial index < 0.80 is associated with elevated 
blood pressure, particularly systolic blood pressure. 
RETINOPATHY
Retina is an end organ which is frequently damaged in hypertensives(67)
Retina is a window to the vascular remodelling happening in the pathogenesis of 
hypertension as described previously. There are various classification System proposed 
for hypertensive retinopathy. In our study we have applied the most widely used Keith 
wagner’s system of grading hypertensive retinopathy.
KEITH WAGNER’S GRADING   
STAGE FEATURES
GRADE 1 Arteriolar narrowing, tortuosity, silver/copper wiring
GRADE 2 AV nipping
GRADE 3 Flame shaped haemorrhages,cotton wool spots and 
hard exudates
GRADE 4  PAPILLOEDEMA
The prevalence of retinopathy varies among the population studied. In a Study  in 
India chowta et al(62)  the prevalence was 33% among the hypertensives 
DEFINING HYPERTENSION
Table below provides a classification of BP for adults 18 years and older (8). The 
classification is based on the average of two or more properly measured, seated, BP 
readings on each of two or more office visits.
Prehypertension is not a disease category(8). Rather, it is a designation chosen to 
identify individuals at high risk of developing hypertension, so that both patients and 
clinicians are alerted to this risk and encouraged to intervene and prevent or delay the 
disease from developing. 
BLOOD PRESSURE
CLASSIFICATION
SYSTOLIC BP DIASTOLIC BP
    NORMAL <120 and<80
 PREHYPERTENSION 120-139 Or 80-99
STAGE 1 HT 140-159 Or100-109
STAGE2 HT ≥160 Or ≥ 110
JNC-7 CLASSIFICATION
Impressive  evidence  has  accumulated  to  warrant  greater  attention  to  the 
importance of SBP as a major risk factor for CVD(63).  .Changing patterns of  BP occur 
with increasing age. The rise in SBP continues throughout life in contrast to DBP, which 
rises until approximately age 50, tends to level off over the next decade, and may remain 
the same or fall later in life . Diastolic hypertension predominates before age 50, either 
alone or  in combination with SBP elevation.The prevalence of  systolic  hypertension 
increases with age, and above 50 years of age, systolic hypertension represents the most 
common form of hypertension. DBP is a more potent cardiovascular risk factor than 
SBP until age 50 thereafter, SBP is more important (63). If the rise in BP with age could be 
prevented or diminished, much of hypertension, cardiovascular and renal disease, and 
stroke might be prevented. A number of important causal factors for hypertension have 
been identified, including  excess body weight; excess dietary sodium intake ,reduced 
physical  activity;  inadequate  intake  of  fruits,  vegetables,  and  potassium;  and  excess 
alcohol intake.(64)
Essential Hypertension
Essential hypertension tends to be familial and is likely to be the consequence of 
an interaction between environmental and genetic factors. The prevalence of essential 
hypertension increases with age, and individuals with relatively high blood pressures at 
younger ages are at increased risk for the subsequent development of hypertension. It is 
likely  that  essential  hypertension  represents  a  spectrum  of  disorders  with  different 
underlying pathophysiologies. In the majority of patients with established hypertension, 
peripheral resistance is increased and cardiac output is normal or decreased; however, in 
younger patients with mild or labile hypertension, cardiac output may be increased and 
peripheral resistance may be normal. 
When plasma renin activity (PRA) is plotted against 24-h sodium excretion, ~10–
15% of  hypertensive  patients  have  high  PRA and  25% have  low PRA.  High-renin 
patients may have a vasoconstrictor form of hypertension, whereas low-renin patients 
may have a volume-dependent hypertension. Inconsistent associations between plasma 
aldosterone  and  blood  pressure  have  been  described  in  patients  with  essential 
hypertension. The association between aldosterone and blood pressure is more striking 
in African Americans, and PRA tends to be low in hypertensive African Americans. This 
raises the possibility that subtle increases of aldosterone may contribute to hypertension 
in at least some groups of patients who do not have overt primary aldosteronism. 
METABOLIC SYNDROME
The IDF criteria for diagnosing metabolic syndrome has been used for this study .
(65)  
 Metabolic syndrome is defined in the presence of waist circumference of more 
than 90cm for male and 80 cm for female with any of the following 2 criteria.
1. A triglyceride level of more than 150mg/dl or specific medication
2. a fasting plasma glucose of >100mg/dl or a known type2 diabetic
3. a known HT or BP>135/85mm of HG 
4. HDL cholesterol<40 and <50mg/dL for men and female respectively.
ASSOCIATED DISEASES WITH METABOLIC SYNDROME
Cardiovascular Disease
The relative risk for new-onset CVD in patients with the metabolic syndrome, in 
the absence of diabetes, averages between 1.5- and threefold. In an 8-year follow-up of 
middle-aged men and women in the Framingham Offspring Study (FOS), the population 
attributable risk for patients with the metabolic syndrome to develop CVD was 34% in 
men and 16% in women. In the same study, both the metabolic syndrome and diabetes 
predicted ischemic stroke with greater risk for patients with the metabolic syndrome 
than for diabetes alone (19% vs 7%), particularly in women (27% vs 5%) (66)  Patients 
with metabolic syndrome are also at increased risk for peripheral vascular disease.
Type 2 Diabetes
Overall, the risk for type 2 diabetes in patients with the metabolic syndrome is 
increased three-  to fivefold.  In the FOS's  8-year  follow-up of middle-aged men and 
women, the population-attributable risk for developing type 2 diabetes was 62% in men 
and 47% in women.
Etiology
Insulin Resistance 
The most accepted and unifying hypothesis to describe the pathophysiology of the 
metabolic syndrome is insulin resistance, caused by an incompletely understood defect 
in  insulin  action.  The  onset  of  insulin  resistance  is  heralded  by  postprandial 
hyperinsulinemia, followed by fasting hyperinsulinemia and, ultimately, hyperglycemia.
An  early  major  contributor  to  the  development  of  insulin  resistance  is  an 
overabundance of circulating fatty acids . Plasma albumin-bound free fatty acids (FFAs) 
are derived predominantly from adipose tissue triglyceride stores released by hormone-
sensitive lipase. Fatty acids are also derived through the lipolysis of triglyceride-rich 
lipoproteins in tissues by lipoprotein lipase (LPL). Insulin mediates both antilipolysis 
and the  stimulation of  LPL in adipose tissue.  Of  note,  the inhibition of  lipolysis  in 
adipose tissue is the most  sensitive pathway of insulin  action(67). Thus,  when insulin 
resistance  develops,  increased  lipolysis  produces  more  fatty  acids,  which  further 
decrease  the  antilipolytic  effect  of  insulin.  Excessive  fatty  acids  enhance  substrate 
availability and create insulin resistance by modifying downstream signaling. Fatty acids 
impair insulin-mediated glucose uptake and accumulate as triglycerides in both skeletal 
and cardiac muscle, whereas increased glucose production and triglyceride accumulation 
are seen in liver.
The  oxidative  stress  hypothesis  provides  unifying  theory  for  aging  and  the 
predisposition  to  the  metabolic  syndrome.  In  studies  carried  out  in  insulin-resistant 
subjects with obesity or type 2 diabetes, in the offspring of patients with type 2 diabetes, 
and  in  the  elderly,  a  defect  has  been  identified  in  mitochondrial  oxidative 
phosphorylation, leading to the accumulation of triglycerides and related lipid molecules 
in muscle. The accumulation of lipids in muscle is associated with insulin resistance.
OBESITY
Overweight and obesity are defined as abnormal or excessive fat accumulation 
that presents a risk to health. A crude population measure of obesity is the body mass 
index (BMI), a person’s weight (in kilograms) divided by the square of his or her height 
(in metres). A person with a BMI of 25 or more is generally considered obese. A person 
with a BMI equal to or more than 23 is considered overweight(68) .
Overweight and obesity are major risk factors for a number of chronic diseases, 
including diabetes, cardiovascular diseases and cancer. Once considered a problem only 
in high income countries, overweight and obesity are now dramatically on the rise in 
low- and middle-income countries, particularly in urban settings.
 Recent  guidelines  have  reduced the  cut-off  for  Indian population  based on various 
studies. The new WHO Asia Pacific guidelines defines generalised obesity as BMI>25 







30 AND ABOVE OBESE 2
classification of weight by BMI for adult asians
ERECTILE DYSFUNCTION
Erectile  dysfunction  (ED) is  defined as  the persistent  inability  to  achieve  and 
maintain an erection sufficient to permit satisfactory sexual intercourse.(69) Incidence and 
prevalence  of  ED  are  considerable  and  awareness  is  growing  that  the  condition  is 
treatable. Despite the increasing demand for clinical services and the potential impact of 
ED  and  other  sexual  disorders,  on  interpersonal  relationships  and  quality  of  life, 
epidemiological data are relatively scarce. 
The prevalence of ED depends on the population studied and the definition and 
methods used. Since ED often accompanies aging and is associated with chronic illness, 
such as  diabetes  mellitus,  heart  disease,  hypertension,  and a  variety  of  neurological 
diseases,  very  few  studies  have  been  carried  out  to  establish  the  incidence  and 
prevalence of this condition in a healthy population. In a community-based survey of 
men between the ages of 40 and 70 y, 52% of the respondents reported some degree of 
erectile difficulty
In  the present study the abridged 5-item version of the International Index of 
Erectile Function (IIEF-5)(70) as a diagnostic tool for establishing the prevalence of ED is 
used in the Evaluation of newly diagnosed males.
 In one study it  was conclusively proved that  HT patients  had not only more 
incidence of ED but also more severe form of ED(71).
In another study the prevalence of ED among patients with metabolic syndrome 
was  proven  to  be  higher.  At  present  it  has  been  accepted  that  HT  and  MS  are 
independent risk factors for the development of ED.
Various questionnaire has been used to identify ED among the population. The 
widely used International Index of Erectile Function-5 questionnaire(70) has been used in 
our study.
The use of simplified version of the IIEF questionnaire has been proved to be 
useful and reliable in the evaluation of ED in large number of men. (70)
IIEF-5 scoring system
 Score
Over the past six 
months:
1 2 3 4 5
How do you rate 
your confidence that 
you could get and 
keep an erection?
Very low Low Moderate High Very high
When you had 
erections with sexual 
stimulation, how 





















often were you able 
to maintain your 





















difficult was it to 
maintain your 









When you attempted 
sexual intercourse, 

















The IIEF-5 score is the sum of questions 1 to 5. The lowest score is 5 and the highest 
score 25.
severe (5-7), moderate (8-11), mild to moderate (12-16), mild (17-21), and no ED (22-25).
LIPID ABNORMALITIES
Dyslipidemias are more common in patients with metabolic syndrome and in HT. 
However the distribution of lipid abnormalities among newly detected hypertensives is 
not well studied. Dyslipidemias constitute one the major risk factor for coronary heart 
disease as proven by the Framingham heart studies.
Current  lipid  abnormalities  are  defined  by  Adult  Treatment  Panel  3(ATP3) 
guidelines  published  by  the  National  Cholesterol  Education  Progarmme (NCEP)  Of 
United states(72)
ATP III Classification of LDL, Total, and HDL Cholesterol (mg/dL)
LDL CHOLESTEROL
<100 OPTIMAL













Estimating 10-Year Risk for Men and Women
Risk assessment for determining the 10-year risk for developing CHD is carried 
out  using  Framingham risk  scoring(72). The  risk  factors  included  in  the  Framingham 
calculation of 10-year risk are: age, total cholesterol, HDL cholesterol, systolic blood 
pressure, treatment for hypertension, and cigarette smoking. The first step is to calculate 
the  number  of  points  for  each  risk  factor.  For  initial  assessment,values  for  total 
cholesterol and HDL cholesterol are required. Because of a larger database, Framingham 
estimates  are  more  robust  for  total  cholesterol  than  for  LDL  cholesterol.  Total 
cholesterol  and  HDL  cholesterol  values  should  be  the  average  of  at  least  two 
measurements obtained .The blood pressure value used is that obtained at the time of 
assessment, regardless of whether the person is on anti-hypertensive therapy. However, 
if the person is on antihypertensive treatment, an extra point is added beyond points for 
the  blood  pressure  reading  because  treated  hypertension  carries  residual  risk  .  The 
average of several blood pressure measurements, as recommended by the Joint National 
Committee (JNC), is needed for an accurate measure of baseline blood pressure. The 
designation “smoker” means any cigarette smoking in the past month. The 10-year risk 
for myocardial infarction and coronary death (hard CHD) is estimated from total points, 
and the person is categorized according to absolute 10-year risk
Risk Assessment Tool for Estimating 10-year Risk of Developing Hard CHD 
(Myocardial Infarction and Coronary Death) 
The risk assessment tool below uses recent data from the Framingham Heart 
Study to estimate 10-year risk for “hard” coronary heart disease outcomes 
(myocardial infarction and coronary death). This tool is designed to estimate risk 
in adults aged 20 and older who do not have heart disease or diabetes. Use the 
calculator below to estimate 10-year risk.
Age: years 
Gender: Female Male 
Total Cholesterol: mg/dL 
HDL Cholesterol: mg/dL 
Smoker: No Yes 
Systolic Blood Pressure: mm/Hg 
Currently on any medication to treat high blood 
pressure. No Yes 
Calculate  10-Year Risk
Total cholesterol - Total cholesterol values should be the average of at least two 
measurements obtained from lipoprotein analysis. 
HDL cholesterol - HDL cholesterol values should be the average of at least two 
measurements obtained from lipoprotein analysis. 
Smoker - The designation “smoker” means any cigarette smoking in the past 
month. 
Systolic blood pressure - The blood pressure value used is that obtained at the 
time of assessment, regardless of whether the person is on antihypertensive 
therapy (treated hypertension carries residual risk). 
More Information - Determining 10-year (short term) risk for developing CHD 
is carried out using Framingham risk scoring. The risk factors included in the 
Framingham calculation  are  age,  total  cholesterol,  HDL cholesterol,  systolic 
blood pressure, treatment for hypertension, and cigarette smoking. Because of a 
larger database, Framingham estimates are more robust for total cholesterol than 
for LDL cholesterol. Note, however, that LDL cholesterol remains the primary 
target of therapy. The Framingham risk score gives estimates for “hard CHD” 
which includes myocardial infarction and coronary death. 
MATERIALS AND METHODS
SETTING
This study is conducted in the Hypertension clinic of Madras Medical  College 




This  study  was  conducted  over  a  period  of  6  months  from  May2009  to 
October2009.
STUDY POPULATION
Patients attending the hypertensive clinic who are yet to be started on any Drugs.
TYPE OF STUDY
It’s a cross sectional study of patients attending hypertension clinic.
INCLUSION CRITERIA
1. Age  greater than  18 years.
2. patients newly diagnosed as hypertensives in out patient department
EXCLUSIION CRITERIA
1.  Age  less  than 18yrs
2.  known  hypertensives  who  have  discontinued  drugs  and  have  now come  for 
treatment or with complications
3. Known DM patient under antiproteinuria therapy
4. Known CKD/ hypothyroid
5. Known case  of  secondary  HT or  during  evaluation  found  to  have  secondary 
causes.
6. Patients who are already under anti hypertensive drugs for other indiacations like 
CAHD,etc.
SAMPLE SIZE
 100 patients who came for the registration were taken for the study.
 METHODS
       All patients underwent CBC,GTT, serum electrolytes, urea, creatinine,    LFT, 
fasting  lipid  profile,  serum  calcim,  uric  acid,  ecg,  echo,  USG  abdomen,urine  for 
microalbuminuria  after  giving  written  consent.  A  detailed  examination  to  ruleout 
secondary causes were done. BP was measured and staged.The classification is based on 
the average of two or more properly measured, seated BPreadings on each of two or 
more office visits.
A standard proforma was used to record all variables for every individual patient.
STATISTICAL ANALYSIS
Data  analysis  was  done  with  use  of  SPSS  software  version10.  Descriptive 
statistics were used to calculate frequency. To examine the linear trend of proportions, 
trend chi-square was used and to find the test of association chi-square was computed.
RESULTS





In our study the male to female ratio is 1.38:1
SEX NO OF PATIENTS
FEMALE 42
MALE 58




















TABLE SHOWING THE AGE DISTRIBUTION IN NEWLY DIAGNOSED 
HYPERTENSIVES
AGE 30-39 40-49 50-59 >60 TOTAL
F - 12 19 11 42
M 7 23 18 10 58
RATIO - 1.9:1 0.9:1 0.9:1 1.38:1
In our study 45% of female are in age group of 50 to 59 whereas 39% of  males 
are in age group of 40 to 49. The p value was<0.05 significant.




















TABLE SHOWING THE DISTRIBUTION OF  HT STAGE  AMONG THE 
SEXES
ISH STAGE1 STAGE2 TOTAL
F 6 11 25(59.5%) 42
M 6 29(50%) 23 58
In our study females tend to present  in stage 2 HT( 59.5%) , whereas males  tend 
to present a little earlier in stage 1 HT (50%). The P value was <0.05.

























30-39 40-49 50-59 60& ABOVE
ISH 0 0 0 12
STAGE1 7 24 9 0
STAGE2 0 11 28 9
 In this study  the prevalence of ISH was 12% and almost all exclusively occurred 
in patients of more than 60 yrs
SYMPTOM  DISTRIBUTION  AMONG   THE  HYPERTENSIVES
TABLE SHOWING THE DISTRIBUTION OF SYMPTOMS
SEX
F % M %
EPISTAXIS No 41 55
yes 1 3% 3 5%
GIDDINESS No 18 41
yes 24 57% 17 29%
OCCIPITAL HEADACHE No 34 53
yes 8 19% 5 9%
CLAUDICATION No 32 45
yes 10 24% 13 22%
ASYMPTOMATIC 13 31% 30 52%
In our study the predominant symptom  was giddiness  but however males tend to 
present asymptomatic  more.





















TABLE SHOWING THE DISTRIBUTION OF RETINOPATHY
SEX RETINOPATHY TOTAL PERCENTAGE
M 17 58 29%
F 20 42 47.6%
In our study the prevalence of retinopathy among the females was 47.6% and 
among the males was 29%. The P value was<0.05    and it is statistically significant.


















DISTRIBUTION OF MICRO ALBUMINURIA
MICRO
ALBUMINURIA
Nil present PERCENTAGE TOTAL
F 24 18 42.90% 42
M 39 19 32.70% 58
In our study the prevalence of albuminuria was 42.9% among females and  32.7% 
in males with a p value of>0.05 not statistically significant.






















                   DISTRIBUTION OF CARDIAC INVOLVEMENT
GR1DD GR2DD LVH N TOTAL PERCENTAGE
F 13 3 4 22 42 47.6%
M 7 4 15 32 58 44.8%
In this study the prevalence of cardiac changes was 47.6% among females and 
44.8% among males with a p value of <0.05 which is statistically significant.



















DISTRIBUTION OF ABPI  IN HT
ABPI <0.9 >0.9 TOTAL PERCENTAGE
   F 10 32 42 23%
   M 18 40 58 31%
In this study the prevalence of  PVD among females was 23% and 31% among 
males with a p value of >0.05 not significant.




















TABLE  SHOWING THE LDL ABNORMALITIES




F 2 25 13 1 1 35.7%
M 5 33 14 3 3 34.48%
In this study 35.7% of  females and 34.48% of males had dyslipidemia that is a 
LDL level of more than 130mg/dL.

























CHOLESTEROL DISTRIBUTION AMONG THE HT
TOTAL 







 In this study   48% of newly detected HT had hypercholesterolemia.  42.8% of 
females and 51.7% of males had hypercholesterolemia. 

















DISTRIBUTION OF METABOLIC SYNDROME
NO MS MS PRESENT
Count % Count %
SEX F 17 40.50% 25 59.50%
M 31 53.40% 27 46.60%
In our study 59.5% of females 46.6% of males had metabolic syndrome. The p 
value was <0.05 and statistically significant.



















DISTRIBUTION OF BMI GENERALISED OBESITY
<23 23-24.9 25-29.9 30 & 
ABOVE
PERCENTAGE
F 12 27 3 71%
M 1 20 35 2 63%
 In our study the prevalence of obesity was67% and  71% of females and 63% of 
males were found to be obese.

























F 19 6 17 54.70%
M 25 14 19 56.80%
In our study 54.7% of females and  56.8% of males had a 10 years Framingham 
risk score of more than 10%.
DIABETES MELLITUS AMONG THE NEW HT









neg Pos neg pos
F
M
39 3 30 12 15 35.7%
57 1 48 10 11 19%
In this study 26% were diabetic  out of which 22% were newly diagnosed.  35.7% 
of females and 19%  of males were diabetic. The p value was < 0.05 and Significant.


















EQUIVALENT  >10% TOTAL<10% 10-20%
NO
YES
31 9 8 35.4% 48
13 11 28 75% 52
   
In our study 75% of persons with CVS risk score >10% had metabolic syndrome . 






DISTRIBUTION OF ED  AMONG MALES
MILD MODERATE ABSENT PERCENTAGE
M 12 12 34 41.3%














F 31 11 73.8%
M 29 29 50%
In our study the prevalence of abdominal obesity was 60% of the new HT . 73.8% 
of females and 50% of males had abdominal obesity with a p value of  <0.05 which is 
significant.
DISCUSSION
In  our  present  study  applying  the  JNC-7  criteria  100  newly  diagnosed 
hypertensive patients were included after excluding secondary hypertension.
SEX DISTRIBUTION AND HYPERTENSION
There were 58 males and 42 females in our study with a male to female ratio of 
1.38:1. In the CURES study(1) conducted by Mohan et al  in the suburban population 
around Chennai,  after screening 2,350 individuals they found that the male to female 
ratio was 1.35:1. This is almost similar to our study.
AGE GROUP AND HYPERTENSION
The mean age of our patient group was 52  yrs. The mean age of diagnosis for 
females is  54.3 and for  males it  is  50.  However  the sex ratio  was  not  the  same in 
different age groups. None of the females were below 40yrs of age. Similarly 45% of 
females presented between 50 to 59yrs of age whereas 39% of males  diagnosed  were 
between 40-49yrs of age. The p value was<0.05 and significant implying that females 
tend to present late.
STAGES OF HT AMONG THE NEWLY DETECTED PATIENTS
 In our study 40% of patients had stage 1 HT, 48% had stage 2 HT and 12% 
presented with isolated systolic HT. However  59.5% of females presented in stage 2 HT 
whereas 50% of males presented with stage 1 HT. p value was <0.05 and significant 
implying, female tend to present late.
In the CURES1 study by Mohan et al the prevalence  of ISH among persons more 
than 60yrs was 25.2%. In our study the prevalence of ISH among patients aged more 
than 60 was 57%
PREVALENCE OF ISH AMONG THE ELDERLY(>60yrs AGE)
Stage of HT PRESENT STUDY CURES STUDY
Isolated systolic HT 57% 25.2%
 
SYMPTOMS AMONG THE HYPERTENSIVES
43%  of  our  patients  were   completely  asymptomatic  implying  that  routine 
screening  is  necessary  to  identify  hypertension.  Among  the  symptomatic  57% 
complained  of  giddiness.  Males  (52%)  tend  to  be  asymptomatic  more  than 
females(31%). p value was <0.05 and significant. To the best of our knowledge no study 
compared the symptoms of HT with sexes. 
RETINOPATHY AND HYPERTENSION
 In our study 37%  of patients had retinopathy.20% had Gr1 and 17% had Gr2 
retinopathy. 47.6% of females and 29% of males presented with retinopathy.
The p value was <0.05,  statistically  significant.  This implies that   females are 
diagnosed more after the onset of complication. In a study conducted by Chowta et al 
(62)the prevalence  of  retinopathy among the  south  Indians  was 33% which is  almost 
similar to our study.
MICROALBUMINURIA AND HYPERTENSION
In  our  study  the  prevalence  of  microalbuminuria  was  37%.  The  difference 
between the sexes  in our study was not statistically significant. In the study by Biachi et 
al(73) about  microalbuminuria  among  patients  with  HT  the  authors  found  that  the 
incidence of microalbuminuria was 62% which is more than our study.
CARDIAC INVOLVEMENT IN HT
 In our study 46% of patients showed cardiac involvement. 19 showed LVH, 20 
Gr1  DD  and  7  showed  Gr2  DD.  The  p  value  between  the  sexes  was  <0.05  and 
significant again implying female  tend to present more  with complications compared to 
males. In the study by Chowta et(62) al the prevalence of cardiac involvement was 49.5% 
almost near to our study. 
ABPI IN NEW HYPERTENSIVES
 28% of patients had a ABPI of <0.9 signifying the presence of peripheral vascular 
disease among the newly diagnosed hypertensives.  31% of male and 28% of females 
had a ABPI of <0.9.  However the p value was >0.05 and not significant. The observed 
difference could be due to the prevalence of smoking among males. To the best of our 
knowledge we couldn’t find studies comparing ABPI in newly detected hypertensives.
LDL ABNORMALITIES IN NEW HYPERTENSIVES.
In our study the dysipidemia was present in 35% of patients. 35% among females 
and 35.7% among males. However p value was not significant. In the CURES (1)study by 
Mohan  et  al  38%  had  dyslipidemia  which  is  almost  similar  to  our  study.
          HYPERCHOLESTEROLEMIA IN NEW HYPERTENSIVES    
 48% of our patients had hypercholesterolemia. 42.8% of females and 51.7%  of 
males showed abnormal cholesterol values. However the p value was >0.05 and not 
statistically  significant.  In  the  CURES(1) study  by  Mohan  et  al  the  prevalence  of 
hypercholesterolemia was  29.3% .
METABOLIC SYNDROME IN NEW HYPERTENSIVES
 52% of  our  patients  had metabolic  syndrome as defined by the International 
Diabetic federation criteria. Of this 59.5% were females and 46.6% were males and the 
p value was <0.05 statistically significant. Corriea et al(74) showed that the prevalence of 
metabolic syndrome among hypertensives was 48% which is  near to our study.
BODY MASS INDEX IN NEW HYPERTENSIVES
 67% of patients in our study had a BMI of more than 25 which is defined as the 
general abdominal obesity. 71% of females and 63% of males were obese. 
However p value was> 0.05 and not significant. In the CURES(1) study by Mohan 
et al the prevalence of generalised obesity by following a similar criteria was 28.5%. 
FRAMINGHAM RISK SCORE IN NEW HYPERTENSIVES
56% of our patients had a cardio vascular risk score for hard incidents in the next 
10 years of more than 10%. 54.7% of females and 56.8% of males had a risk of more 
than 10%.
 36% of our new hypertensives had coronary heart disease equivalents. Out of this 
36, 26 had diabetes, 6 had peripheral vascular disease and 4 had a risk score Of more 
than 20%. This again stresses the importance of early screening.
DIABETES IN NEW HYPERTENSIVES
 26% of our patients were found to have diabetes. 35.7% of females and 19% of 
males were found to be diabetic. The p value was significant <0.05. in the CURES (1) 
study by Mohan et al the prevalence of diabetes was 31.8% among the hypertensives 
which is almost near to our study.
ABDOMINAL OBESITY IN NEW HYPERTENSIVES
60% of our patients had abdominal obesity. 73.8% of females and 50% of males 
had abdominal obesity as per the revised WHO Asian Pacific guidelines.
The p value was <0.05 and significant. In the CURES (1)study by Mohan et al  The 
prevalence of abdominal obesity was only 26.1%
ERECTILE DYSFUNCTION IN NEW HYPERTENSIVE MALES
41.3% of males had mild to moderate erectile dysfunction in our study. Burchardt 
et al(71) in a study found that the prevalence of erectile dysfunction among hypertensives 
was 68.3%. However this difference might be because this study was done in patients 
who were  under treatment for HT and probably the higher incidence might be due to the 
beta  blockers  or  diuretics  which  those  patients  may  be  taking.  To  the  best  of  our 
knowledge we couldn’t get studies on ED in newly detected hypertensives in India.
METABOLIC SYNDROME WITH CVS RISK SCORING
In our study 75% of patients with metabolic syndrome  had a CVS hard risk score 
of  >10%.  The  p  value  was<0.01  highly  significant.  This  implies  that  metabolic 
syndrome  is a strong predictor of future coronary events.
LIMITATIONS OF THE STUDY
1. This study is done at a tertiary care centre and not at the primary level.
2. The population studied is very small compared with other studies.
3. Endocrine  abnormalities  which may  cause  secondary  HT were  ruled  out  only 
clinically and not biochemically.
4. There was no control population for the results to be compared.
5. Carotid and vertebral Doppler studies were not done.
6. Renal Doppler was not done to rule out reno vascular HT.
CONCLUSION
1. 59%  of newly diagnosed hypertensives had some form of end organ damages.
2. 52% of newly diagnosed hypertensives had metabolic syndrome and 75% among 
them had a CHD risk score of more than 10%.
3. 41.3% of males had erectile dysfunction among them. So when a antihypertensive 
is choosen for a male patient this should be taken into consideration.
4. 67%  of patients had a BMI >25 that is they had obesity.
5. 56% of  newly detected hypertensives have a CHD risk score of more than10% . 
So aggressive risk reduction is necessary.
6. Females tend to present late with more complications compared to males.
7. As diabetes,  hypertension is also a multisystem disease and each hypertensive 
patient has to be individualised and managed.
8.  Finally  it’s  high  time  that  a  routine  screening  programme  is  initiated  at 
Community level to identify HT at early stages itself  so that complications are 
averted. 
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PROFORMA
Name:                                        Age:                     Sex: 
Occupation: 
Place of living: village/town/city:
annual income:
SYMPTOMS:
Epistaxis:                                                                occipital headache:
Giddiness: yes/no                                                   Chest pain: yes/no
Pedal edema: yes/no                                              TIA: yes/no
Episodic Headache/palpitations/perspiration       CVA: yes/no 
Weight gain: yes/no                                              hyperpigmentation: yes/no
Visual disturbance:                                               claudication: yes/no
                           
HISTORY:
Sexual dysfunction:  
Physical activity:
Drug abuse: cocaine/steroids/NSAID/ephedrine
Diabetes: yes/no                               Renal disease: yes/no
Thyroid disease: yes/no                      CAHD: yes/no
Smoker: yes/no                                   Alcoholism: yes/no
TIA/CVA: yes/no
Family history:     HT:                                       DM:          
                       CKD:                           premature CVS:
O/E:
Facies:                                                             pallor:
Xanthoma:                                                      Xanthelasma:
Purple striae:                                                   Thyroid gland:
Waist circumference:                                       Hyperpigmentation:
Pedal edema:                                                    Built:
      JVP:
        PR:
         Carotid bruit:
          Radiofemoral delay:
          Peripheral pulses:
     BP in Rt UL:                        Stage:
               Lt UL:
CVS:
    Apical impulse position:
                   Heart sounds:
                  Added sounds:
                          Murmurs:
P/A
     Organomegaly:                               pulsations:





Hb:            Htc:        Tc:                              Dc:           Platelets:
Urea:                                                                 creatinine:
Creatinine clearance:
Calcium:                                            Na+:               K+ :                  
Lipid profile:                                                               
Total cholesterol:                                                        
Triglycerides-                                HDL:                    
LDL:                                            VLDL:                   
 ECG:




WAIST CIRCUMFERENCE:                                         BMI:
METABOLIC SYNDROME: YES/NO
VHD RISK SCORE:
CHD EQUIVALENT:
ERECTILE DYSFUNCTION:
LIVER FUNCTION RESULT:

